# Clinical and Prognostic Value of VHL in Korean Patients with Rectal Cancer

**Authors:** Sang-Won Moon, Jun-Chae Lee, Jae-Ho Lee, Tae-Young Kim, Jong Ho Park

PMC · DOI: 10.3390/medicina61020306 · 2025-02-10

## TL;DR

This study explores the role of VHL gene expression in rectal cancer, suggesting it could be a potential biomarker for prognosis and treatment.

## Contribution

The study is the first to correlate VHL gene expression with rectal cancer using patient tissues and TCGA data.

## Key findings

- Lower VHL expression was associated with cancer recurrence and lymphatic invasion in rectal cancer patients.
- VHL gene expression levels correlated with M stage and predicted poorer survival in rectal cancer.
- Findings suggest VHL gene expression could serve as a potential biomarker for rectal cancer prognosis.

## Abstract

Background and Objectives: Von Hippel–Lindau (VHL) disease is caused by mutations in the VHL gene and can develop various cancers. Hypoxia-inducible factors 1 and 2 alphas, regulated by the VHL gene, can increase the levels of vascular endothelial growth factor, thereby activating cancer progression. Here, we demonstrated clinical and prognostic values of VHL expression in rectal cancer (RC). Materials and Methods: Von Hippel–Lindau mRNA expression was examined in 60 patients with RC. Furthermore, we evaluated survival to determine the prognostic significance of VHL mRNA expression levels in RC using the Cancer Genome Atlas (TCGA) data. Results: Lower VHL expression was correlated with the recurrence (p = 0.058) and lymphatic invasion (p = 0.078), although it was not statistically significant. In TCGA data, VHL expression level was correlated with the M stage (p = 0.044); however, it had a possible association with lymphatic invasion (p = 0.068) and N stage (p = 0.104). Survival analysis showed that lower VHL gene expression predicted poorer survival in both patients with RC and TCGA data. Conclusions: This study identified a significant correlation between VHL gene expression and RC for the first time using patient tissues and TCGA data, suggesting that the VHL gene expression level could be a potential biomarker or candidate for the treatment of RC. Further studies are required to identify the molecular pathogenesis and clinical characteristics of VHL disease in RC.

## Linked entities

- **Genes:** VHL (von Hippel-Lindau tumor suppressor) [NCBI Gene 7428]
- **Diseases:** rectal cancer (MONDO:0006519), Von Hippel–Lindau disease (MONDO:0008667)

## Full-text entities

- **Genes:** VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}
- **Diseases:** Cancer (MESH:D009369), RC (MESH:D012004), VHL disease (MESH:D006623), lymphatic invasion (MESH:D008207)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11857133/full.md

---
Source: https://tomesphere.com/paper/PMC11857133